Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science (R21)

Post Date

October 26th 2009

Application Due Date

September 30th 2010

Funding Opportunity Number

RFA-CA-10-001

CFDA Number(s)

93.393
93.394
93.395
93.396

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Eligibility Categories

State Governments
Public and State Controlled Institutions of Higher Education
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $1500000

• Award Range:

  $None - $200000

Grant Description

Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing technically innovative feasibility studies focused on early stage development of cancer-relevant technologies that address the issues related to pre-analytical variations in the collection, processing, handling, and storage of biospecimens or its derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or their derived samples for downstream molecular analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to have a potential to accelerate and/or enhance the research in cancer biology, prevention, diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen and/or sample quality. All projects must include quantitative milestones (i.e. technical metrics that determine whether the specific aims have been accomplished). This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental (R21) grant mechanism, and runs parallel with a FOA of identical scientific scope, RFA-CA-10-002, that solicits applications under the NIH R33 grant mechanism. Funds Available and Anticipated Number of Awards. The NCI intends to commit a total of approximately $1,500,000 to this FOA in fiscal year 2010 to fund up to seven applications in response to this FOA. Budget and Project Period. The total project period for an application submitted in response to this FOA may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-10-001.html